BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. focuses on developing innovative therapies employing artificial intelligence to address critical needs in psychiatry and neurology, aiming to improve patient outcomes through advanced treatment options. Founded in 2017 and headquartered in New Haven, US, BioXcel Therapeutics, Inc. specializes in the development of AI-driven therapies for psychiatric conditions.

The company’s founder, Vimal Mehta, has a background in healthcare innovation and previously founded other ventures. As an investment target, BioXcel raised USD 260. 00 mn in its latest PIPE funding round, which occurred on March 7, 2018, bringing the total amount raised to USD 260. 00 mn across 3 deals.

BioXcel Therapeutics, Inc. specializes in the development and commercialization of therapies that leverage artificial intelligence to meet unmet medical needs, particularly in psychiatry and neurology. Its flagship product, IGALMI, was launched to treat acute agitation associated with bipolar disorders or schizophrenia, utilizing a proprietary formulation for rapid relief. The company serves healthcare professionals, pharmacies, and hospitals primarily in the United States and select international markets, with an ongoing commitment to developing more AI-driven products to improve mental health outcomes.

In the most recent financial year 2024, BioXcel Therapeutics reported revenue of USD 2,266,000 and an EBITDA loss of USD -66,936,000. Their revenue model focuses primarily on prescription sales of IGALMI, with a structured pricing strategy that aligns with the therapeutic's value proposition, aiming to enhance patient outcomes and treatment access. BioXcel Therapeutics plans to expand its product pipeline with additional AI-based solutions designed to address a variety of mental health issues. The company is targeting market expansion into international regions, with efforts planned for the next two years.

The recent funding will support the development and commercialization of new products, as well as the strategic expansion of its market presence. In addition, the funds raised during the USD 60 million IPO in March 2018, which sold 5. 45 million shares at USD 11 per share, will bolster these initiatives.